Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MATINAS BIOPHARMA HOLDINGS, INC.

(MTNB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

11/08/2021 | 06:36am EST

Matinas BioPharma Holdings, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 6.84 million compared to USD 5.45 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.03 a year ago. Diluted loss per share from continuing operations was USD 0.03 compared to USD 0.03 a year ago. For the nine months, net loss was USD 16.58 million compared to USD 16.11 million a year ago. Basic loss per share from continuing operations was USD 0.08 compared to USD 0.09 a year ago. Diluted loss per share from continuing operations was USD 0.08 compared to USD 0.09 a year ago.


ę S&P Capital IQ 2021
All news about MATINAS BIOPHARMA HOLDINGS, INC.
01/18Matinas BioPharma to Provide Corporate Update and 2022 Business Outlook on January 25, ..
AQ
2021Matinas BioPharma Says Data Monitoring Panel Backs Continuation of Meningitis Trial to ..
MT
2021MATINAS BIOPHARMA : Announces Unanimous DSMB Approval to Progress into Fourth and Final Co..
PU
2021MATINAS BIOPHARMA HOLDINGS, INC. : Regulation FD Disclosure, Other Events, Financial State..
AQ
2021Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final C..
GL
2021Matinas Biopharma Announces Unanimous Dsmb Approval to Progress into Fourth and Final C..
CI
2021Matinas BioPharma Holdings Names Chief Business Officer
MT
2021MATINAS BIOPHARMA : Appoints Thomas Hoover, M.B.A. as Chief Business Officer - Form 8-K
PU
2021MATINAS BIOPHARMA HOLDINGS, INC. : Change in Directors or Principal Officers, Regulation F..
AQ
2021Matinas BioPharma Appoints Thomas Hoover, M.B.A. as Chief Business Officer
GL
More news
Analyst Recommendations on MATINAS BIOPHARMA HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 0,47 M - -
Net income 2021 -23,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,98x
Yield 2021 -
Capitalization 177 M 177 M -
Capi. / Sales 2021 376x
Capi. / Sales 2022 44,4x
Nbr of Employees 20
Free-Float 96,0%
Chart MATINAS BIOPHARMA HOLDINGS, INC.
Duration : Period :
Matinas BioPharma Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,82 $
Average target price 2,75 $
Spread / Average Target 235%
EPS Revisions
Managers and Directors
Jerome D. Jabbour President, Chief Executive Officer & Director
Keith A. Kucinski Chief Financial Officer
Herbert J. Conrad Chairman
Raphael J. Mannino Chief Scientific Officer & Senior Vice President
James J. Ferguson Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MATINAS BIOPHARMA HOLDINGS, INC.-18.81%177
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508